Biomedicines (Jun 2022)

Validation of Non-Invasive Preimplantation Genetic Screening Using a Routine IVF Laboratory Workflow

  • Ni-Chin Tsai,
  • Yun-Chiao Chang,
  • Yi-Ru Su,
  • Yi-Chi Lin,
  • Pei-Ling Weng,
  • Yin-Hua Cheng,
  • Yi-Ling Li,
  • Kuo-Chung Lan

DOI
https://doi.org/10.3390/biomedicines10061386
Journal volume & issue
Vol. 10, no. 6
p. 1386

Abstract

Read online

Embryo selection is needed to optimize the chances of pregnancy in assisted reproduction technology. This study aimed to validate non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) using a routine IVF laboratory workflow. Can niPGT-A combined with time-lapse morphokinetics provide a better embryo-selection strategy? A total of 118 spent culture mediums (SCMs) from 32 couples were collected. A total of 40 SCMs and 40 corresponding trophectoderm (TE) biopsy samples (n = 29) or arrested embryos (n = 11) were assessed for concordance. All embryos were cultured to the blastocyst stage (day 5 or 6) in a single-embryo culture time-lapse incubator. The modified multiple annealing and looping-based amplification cycle (MALBAC) single-cell whole genome amplification method was used to amplify cell-free DNA (cfDNA) from the SCM, which was then sequenced on the Illumina MiSeq system. The majority of insemination methods were conventional IVF. Low cfDNA concentrations were noted in this study. The amplification niPGT-A and conventional PGT-A was 67.7%. Based on this study, performing niPGT-A without altering the daily laboratory procedures cannot provide a precise diagnosis. However, niPGT-A can be applied in clinical IVF, enabling the addition of blastocysts with a better prediction of euploidy for transfer.

Keywords